ArticleTheranostics2024
GPAT3 is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma.
Yu Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
9 papers cite it
this papercites it
ArticleTheranostics2024
Yu Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.